

Consolidated Financial Report
for the Year Ended December 31, 2016 (Unaudited)(Japan GAAP)
AnGes MG, Inc. <http://www.anges-mg.com/>

Listings: Mothers of the Tokyo Stock Exchange, Code 4563

Head Office: 4F, Saito Bio-Incubator, 7-7-15, Saito-Asagi, Ibaraki, Osaka, 567-0085, Japan

(Figures are rounded down to the nearest million yen)

1. Business Results for the Year 2016 (From Jan. 1, 2016 to Dec. 31, 2016)
(1) Results of Operations (Percentages indicate changes from the same period of the previous fiscal year)

	Revenues		Operating loss		Ordinary loss		Net loss	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%
FY2016	514	19.6	(4,763)	—	(4,847)	—	(4,776)	—
FY2015	430	(52.7)	(4,171)	—	(4,089)	—	(4,143)	—

*Comprehensive Income FY2016 : (5,182) million yen FY2015 : (4,191) million yen

	Net loss per share	Diluted net loss per share	Return on Equity	Return on asset	Operating profit ratio
	Yen	Yen	%	%	%
FY2016	(75.29)	—	(119.0)	(104.3)	(926.2)
FY2015	(74.53)	—	(70.3)	(63.2)	(969.9)

*Equity in net income of affiliates FY2016 : — million yen FY2015 : — million yen

(2) Financial Position

	Total assets	Total net assets	Shareholders' equity ratio	Net assets per share
	Million yen	Million yen	%	Yen
Dec. 31, 2016	4,539	3,869	85.0	54.65
Dec. 31, 2015	4,751	4,221	87.8	73.75

*Shareholder's equity Dec. 31, 2016 : 3,860 million yen Dec. 31, 2015 : 4,169 million yen

(3) Cash Flows

	Cash flows from operating activities	Cash flows from investing activities	Cash flows from financing activities	Cash and cash equivalents, at end
	Million yen	Million yen	Million yen	Million yen
FY2016	(4,983)	(829)	4,793	995
FY2015	(4,599)	(69)	716	2,068

2. Dividend

	Dividend per share					Dividend (Total)	Dividend payout ratio (Consolidated)	Dividend on equity (Consolidated)
	1Q	2Q	3Q	4Q	Full-year			
	Yen	Yen	Yen	Yen	Yen	Million yen	%	%
FY 2015	—	0.00	—	0.00	0.00	—	—	—
FY 2016	—	0.00	—	0.00	0.00	—	—	—
FY 2017 (Forecast)	—	0.00	—	0.00	0.00	—	—	—

3. Earnings Forecast for the Fiscal Year 2017 (From Jan. 1, 2017 to Dec. 31, 2017)

	Revenues		Operating loss		Ordinary loss		Net loss		Net loss per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
Full-year	360	—	(3,400)	—	(3,400)	—	(3,400)	—	(48.14)

Notes:

(1) Change of reporting entities (change of condition of significant consolidated subsidiaries) : None

(2) Change of significant accounting and reporting policies for consolidated financial statements

1) Changes caused by revision of accounting standard : Applicable

2) Changes in accounting policies other than 1) : None

3) Changes in accounting estimates : None

4) Restatement : None

(3) Number of shares issued and outstanding (common stock)

1) Number of shares issued and outstanding (including treasury stock)

Dec. 31, 2016	70,631,061 shares	Dec. 31, 2015	56,544,361 shares
---------------	-------------------	---------------	-------------------

2) Number of treasury stock

Dec. 31, 2016	81 shares	Dec. 31, 2015	38 shares
---------------	-----------	---------------	-----------

3) Average number of shares issued and outstanding

FY2016	63,443,513 shares	FY2015	55,595,693 shares
--------	-------------------	--------	-------------------

(Reference) Summary of Nonconsolidated Financial Reports

1. Business Results for the Year 2016 (From Jan. 1, 2016 to Dec. 31, 2016)

(1) Results of Operations (Percentages indicate changes from the previous term)

	Revenues		Operating loss		Ordinary loss		Net loss	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%
FY2016	514	19.6	(4,796)	—	(4,762)	—	(4,683)	—
FY2015	430	(52.7)	(4,214)	—	(4,131)	—	(4,169)	—

	Net loss per share	Diluted net loss per share
	Yen	Yen
FY2016	(73.82)	—
FY2015	(75.00)	—

(2) Financial Position

	Total assets	Total net assets	Shareholders' equity ratio	Net assets per share
	Million yen	Million yen	%	Yen
Dec. 31, 2016	4,452	3,777	84.6	53.36
Dec. 31, 2015	4,572	4,017	86.7	70.14

*Shareholder's equity Dec. 31, 2016 : 3,768 million yen Dec. 31, 2015 : 3,966 million yen

*Performance forecasts or any other future events contained in this report are based on currently available information which are believed to be reasonable at the time of forecasts. Actual results may differ from the forecasts due to various factors.

**This financial report has been translated from Japanese original which has been prepared in accordance with generally accepted accounting principles in Japan, for reference purposes only. Also some changes are added to this report in order to present in a form more familiar to the readers outside Japan.

AnGes MG, Inc
Consolidated Balance Sheets
(In thousands of yen)
(Unaudited)

	December 31, 2015	December 31, 2016
Assets		
Current assets		
Cash and deposits	2,074,872	995,620
Accounts receivable - trade	135,263	298,318
Merchandise	111,852	170,069
Raw materials and supplies	555,552	1,001,197
Advance payments - trade	1,208,868	951,147
Prepaid expenses	27,217	27,057
Consumption taxes receivable	126,656	166,078
Other	5,075	9,973
Allowance for doubtful accounts	(2,578)	-
Total current assets	4,242,782	3,619,461
Non-current assets		
Property, plant and equipment		
Buildings	71,283	71,269
Accumulated depreciation	(45,600)	(49,193)
Buildings, net	25,682	22,076
Tools, furniture and fixtures	245,236	265,291
Accumulated depreciation	(195,262)	(211,464)
Tools, furniture and fixtures, net	49,974	53,826
Total property, plant and equipment	75,657	75,902
Intangible assets		
Patent right	39,929	31,588
Other	11,279	23,566
Total intangible assets	51,208	55,155
Investments and other assets		
Investment securities	315,062	720,500
Lease and guarantee deposits	51,551	51,470
Other	15,732	16,710
Total investments and other assets	382,345	788,682
Total non-current assets	509,211	919,739
Total assets	4,751,994	4,539,201

AnGes MG, Inc
Consolidated Balance Sheets
(In thousands of yen)
(Unaudited)

	December 31, 2015	December 31, 2016
Liabilities		
Current liabilities		
Accounts payable - trade	246,560	389,126
Accounts payable - other	83,364	62,111
Accrued expenses	23,357	87,702
Income taxes payable	33,399	80,703
Advances received	82,902	1,449
Deposits received	12,296	9,824
Total current liabilities	481,880	630,917
Non-current liabilities		
Deferred tax liabilities	26,402	16,255
Asset retirement obligations	22,354	22,646
Total non-current liabilities	48,756	38,902
Total liabilities	530,637	669,819
Net assets		
Shareholders' equity		
Capital stock	15,214,941	17,651,190
Capital surplus	13,525,681	15,961,930
Retained earnings	(24,570,961)	(29,347,742)
Treasury shares	(11)	(23)
Total shareholders' equity	4,169,648	4,265,354
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	(29,942)	(416,779)
Foreign currency translation adjustment	30,210	11,484
Total accumulated other comprehensive income	268	(405,295)
Subscription rights to shares	51,439	9,322
Total net assets	4,221,356	3,869,382
Total liabilities and net assets	4,751,994	4,539,201

AnGes MG, Inc
Consolidated Statements of Operations
(In thousands of yen)
(Unaudited)

	Year ended Dec. 31, (From Jan. 1 to Dec.31)	
	2015	2016
Business revenues		
Net sales of goods	350,113	346,792
Research and development revenues	80,041	167,477
Total business revenues	430,154	514,269
Business expenses		
Cost of sales	179,702	174,511
Research and development expenses	3,532,691	4,188,510
Selling, general and administrative expenses	889,744	914,588
Total business expenses	4,602,139	5,277,611
Operating loss	(4,171,985)	(4,763,341)
Non-operating income		
Interest income	1,103	531
Foreign exchange gains	21,099	-
Subsidy income	72,811	-
Commission fee	4,318	7,264
Gain on sales of registered trademarks	-	1,000
Miscellaneous income	3,379	136
Total non-operating income	102,712	8,933
Non-operating expenses		
Share issuance cost	19,036	86,838
Loss on investments in partnership	1,053	-
Foreign exchange losses	-	4,252
Miscellaneous loss	-	1,798
Total non-operating expenses	20,089	92,889
Ordinary loss	(4,089,362)	(4,847,297)
Extraordinary income		
Gain on sales of investment securities	-	44,510
Gain on reversal of subscription rights to shares	57,780	42,117
Total extraordinary income	57,780	86,627
Extraordinary losses		
Loss on valuation of investment securities	92,569	-
Total extraordinary losses	92,569	-
Loss before income taxes	(4,124,150)	(4,760,670)
Income taxes - current	19,185	15,176
Income taxes - deferred	-	934
Total income taxes	19,185	16,110
Loss	(4,143,335)	(4,776,780)
Loss attributable to owners of parent	(4,143,335)	(4,776,780)

AnGes MG, Inc
Consolidated Statements of Comprehensive Income
(In thousands of yen)
(Unaudited)

	Year ended Dec. 31, (From Jan. 1 to Dec.31)	
	2015	2016
Loss	(4,143,335)	(4,776,780)
Other comprehensive income		
Valuation difference on available-for-sale securities	(46,948)	(386,837)
Foreign currency translation adjustment	(824)	(18,726)
Total other comprehensive income	(47,772)	(405,563)
Comprehensive income	(4,191,108)	(5,182,343)
Comprehensive income attributable to:		
owners of parent	(4,191,108)	(5,182,343)
non-controlling interests	-	-

AnGes MG, Inc
Consolidated Statements of Changes in Net Assets
(In thousands of yen)
(Unaudited)

Year ended Dec.31, 2015 (From Jan.1 to Dec.31, 2015)

	Shareholders' equity				
	Capital stock	Capital surplus	Retained earnings	Treasury shares	Total shareholders' equity
Balance at the beginning of the period	14,847,066	13,157,806	(20,427,625)	(11)	7,577,234
Changes of items during the period					
Issuance of new shares	367,875	367,875			735,750
Loss attributable to owners of parent			(4,143,335)		(4,143,335)
Purchase of treasury shares				-	-
Net changes of items other than shareholders' equity					-
Total changes of items during the period	367,875	367,875	(4,143,335)	-	(3,407,585)
Balance at the end of current period	15,214,941	13,525,681	(24,570,961)	(11)	4,169,648

	Accumulated other comprehensive income			Subscription rights to shares	Total net assets
	Valuation difference on available-for-sale securities	Foreign currency translation adjustment	Total accumulated other comprehensive income		
Balance at the beginning of the period	17,005	31,035	48,041	109,165	7,734,440
Changes of items during the period					
Issuance of new shares					735,750
Loss attributable to owners of parent					(4,143,335)
Purchase of treasury shares					-
Net changes of items other than shareholders' equity	(46,948)	(824)	(47,772)	(57,725)	(105,498)
Total changes of items during the period	(46,948)	(824)	(47,772)	(57,725)	(3,513,084)
Balance at the end of current period	(29,942)	30,210	268	51,439	4,221,356

Year ended Dec.31, 2016 (From Jan.1 to Dec.31, 2016)

	Shareholders' equity				
	Capital stock	Capital surplus	Retained earnings	Treasury shares	Total shareholders' equity
Balance at the beginning of the period	15,214,941	13,525,681	(24,570,961)	(11)	4,169,648
Changes of items during the period					
Issuance of new shares	2,436,249	2,436,249			4,872,498
Loss attributable to owners of parent			(4,776,780)		(4,776,780)
Purchase of treasury shares				(11)	(11)
Net changes of items other than shareholders' equity					-
Total changes of items during the period	2,436,249	2,436,249	(4,776,780)	(11)	95,706
Balance at the end of current period	17,651,190	15,961,930	(29,347,742)	(23)	4,265,354

	Accumulated other comprehensive income			Subscription rights to shares	Total net assets
	Valuation difference on available-for-sale securities	Foreign currency translation adjustment	Total accumulated other comprehensive income		
Balance at the beginning of the period	(29,942)	30,210	268	51,439	4,221,356
Changes of items during the period					
Issuance of new shares					4,872,498
Loss attributable to owners of parent					(4,776,780)
Purchase of treasury shares					(11)
Net changes of items other than shareholders' equity	(386,837)	(18,726)	(405,563)	(42,117)	(447,680)
Total changes of items during the period	(386,837)	(18,726)	(405,563)	(42,117)	(351,974)
Balance at the end of current period	(416,779)	11,484	(405,295)	9,322	3,869,382

AnGes MG, Inc
Consolidated Statements of Cash Flows
(In thousands of yen)
(Unaudited)

	Year ended Dec. 31, (From Jan. 1 to Dec.31)	
	2015	2016
Cash flows from operating activities		
Loss before income taxes	(4,124,150)	(4,760,670)
Depreciation	48,983	67,306
Increase (decrease) in allowance for doubtful accounts	2,578	(2,578)
Interest income	(1,103)	(531)
Foreign exchange losses (gains)	(10,642)	32,765
Loss (gain) on investments in partnership	1,053	-
Loss (gain) on sales of short-term and long-term investment securities	-	(44,510)
Loss (gain) on valuation of investment securities	92,569	-
Share issuance cost	19,036	86,838
Share-based compensation expenses	55	-
Gain on reversal of subscription rights to shares	(57,780)	(42,117)
Proceeds from miscellaneous income	(3,044)	-
Decrease (increase) in notes and accounts receivable - trade	523,749	(163,055)
Decrease (increase) in inventories	(310,207)	(503,860)
Increase (decrease) in notes and accounts payable - trade	39,473	141,633
Decrease (increase) in advance payments	(686,948)	255,591
Decrease (increase) in consumption taxes refund receivable	(111,949)	(39,439)
Increase (decrease) in accounts payable - other	29,007	(17,822)
Increase (decrease) in accrued expenses	16,194	65,823
Increase (decrease) in advances received	(33,086)	(81,453)
Decrease (increase) in other current assets	(8,381)	2,702
Decrease (increase) in other non-current assets	(3,825)	(4,596)
Increase (decrease) in other current liabilities	(6,803)	49,755
Increase (decrease) in other non-current liabilities	234	292
Subtotal	<u>(4,584,990)</u>	<u>(4,957,925)</u>
Interest income received	1,103	529
Income taxes paid	(15,529)	(26,299)
Net cash provided by (used in) operating activities	<u>(4,599,416)</u>	<u>(4,983,694)</u>
Cash flows from investing activities		
Payments into time deposits	(6,072)	(5,459)
Proceeds from withdrawal of time deposits	6,055	5,456
Purchase of property, plant and equipment	(45,368)	(49,545)
Purchase of intangible assets	(18,249)	(21,450)
Purchase of investment securities	-	(807,987)
Proceeds from sales of investment securities	87	49,140
Dividends from investment funds	3,676	-
Payments for lease and guarantee deposits	(9,500)	(207)
Proceeds from collection of lease and guarantee	-	238
Net cash provided by (used in) investing activities	<u>(69,371)</u>	<u>(829,815)</u>

AnGes MG, Inc
Consolidated Statements of Cash Flows
(In thousands of yen)
(Unaudited)

	Year ended Dec. 31, (From Jan. 1 to Dec.31)	
	2015	2016
Cash flows from financing activities		
Proceeds from issuance of common shares	716,713	-
Purchase of treasury shares	-	(11)
Proceeds from issuance of shares resulting from exercise of subscription rights to shares	-	4,767,028
Proceeds from issuance of subscription rights to shares	-	26,371
Net cash provided by (used in) financing activities	716,713	4,793,388
Effect of exchange rate change on cash and cash equivalents	9,569	(53,083)
Net increase (decrease) in cash and cash equivalents	(3,942,504)	(1,073,204)
Cash and cash equivalents at beginning of period	6,011,329	2,068,825
Cash and cash equivalents at end of period	2,068,825	995,620

AnGes MG, Inc
Nonconsolidated Balance Sheets
(In thousands of yen)
(Unaudited)

	December 31, 2015	December 31, 2016
Assets		
Current assets		
Cash and deposits	1,842,867	888,867
Accounts receivable - trade	135,263	298,318
Merchandise	111,852	170,069
Raw materials	519,467	964,961
Supplies	36,084	36,236
Advance payments - trade	1,201,432	945,628
Prepaid expenses	24,149	22,918
Consumption taxes receivable	126,635	166,078
Other	4,699	1,780
Allowance for doubtful accounts	(2,578)	-
Total current assets	3,999,874	3,494,858
Non-current assets		
Property, plant and equipment		
Buildings	70,867	70,867
Accumulated depreciation	(45,369)	(48,934)
Buildings, net	25,498	21,933
Tools, furniture and fixtures	223,030	249,800
Accumulated depreciation	(180,087)	(201,218)
Tools, furniture and fixtures, net	42,943	48,581
Total property, plant and equipment	68,441	70,515
Intangible assets		
Patent right	39,929	31,588
Trademark right	79	29
Software	11,044	11,893
Telephone subscription right	86	86
Total intangible assets	51,140	43,597
Investments and other assets		
Investment securities	315,062	720,500
Shares of subsidiaries and associates	71,684	61,684
Long-term prepaid expenses	15,732	10,863
Lease and guarantee deposits	50,903	50,842
Total investments and other assets	453,382	843,891
Total non-current assets	572,964	958,004
Total assets	4,572,839	4,452,862

AnGes MG, Inc
Nonconsolidated Balance Sheets
(In thousands of yen)
(Unaudited)

	December 31, 2015	December 31, 2016
Liabilities		
Current liabilities		
Accounts payable - trade	246,560	375,032
Accounts payable - other	131,994	86,032
Accrued expenses	6,461	85,006
Income taxes payable	26,819	80,543
Advances received	82,902	1,449
Deposits received	11,748	8,931
Total current liabilities	506,486	636,997
Non-current liabilities		
Deferred tax liabilities	26,402	15,320
Asset retirement obligations	22,354	22,646
Total non-current liabilities	48,756	37,967
Total liabilities	555,243	674,965
Net assets		
Shareholders' equity		
Capital stock	15,214,941	17,651,190
Capital surplus		
Legal capital surplus	13,525,681	15,961,930
Total capital surpluses	13,525,681	15,961,930
Retained earnings		
Other retained earnings		
Retained earnings brought forward	(24,744,512)	(29,427,742)
Total retained earnings	(24,744,512)	(29,427,742)
Treasury shares	(11)	(23)
Total shareholders' equity	3,996,098	4,185,354
Valuation and translation adjustments		
Valuation difference on available-for-sale securities	(29,942)	(416,779)
Total valuation and translation adjustments	(29,942)	(416,779)
Subscription rights to shares	51,439	9,322
Total net assets	4,017,595	3,777,897
Total liabilities and net assets	4,572,839	4,452,862

AnGes MG, Inc
Nonconsolidated Statements of Operations
(In thousands of yen)
(Unaudited)

	Year ended Dec. 31, (From Jan. 1 to Dec.31)	
	2015	2016
Business revenues		
Net sales of goods	350,113	346,792
Research and development revenues	80,041	167,477
Total business revenues	430,154	514,269
Business expenses		
Cost of sales	179,702	174,511
Research and development expenses	3,573,391	4,220,512
Selling, general and administrative expenses	891,167	915,381
Total business expenses	4,644,261	5,310,405
Operating loss	(4,214,107)	(4,796,135)
Non-operating income		
Interest income	1,000	506
Dividend income	-	112,210
Foreign exchange gains	21,037	994
Subsidy income	72,811	-
Miscellaneous income	7,697	8,401
Total non-operating income	102,547	122,111
Non-operating expenses		
Share issuance cost	19,036	86,838
Loss on investments in partnership	1,053	-
Miscellaneous loss	-	1,740
Total non-operating expenses	20,089	88,578
Ordinary loss	(4,131,649)	(4,762,602)
Extraordinary income		
Gain on sales of investment securities	-	44,510
Gain on reversal of subscription rights to shares	57,780	42,117
Total extraordinary income	57,780	86,627
Extraordinary losses		
Loss on valuation of investment securities	92,569	-
Loss on liquidation of subsidiaries	-	2,415
Total extraordinary losses	92,569	2,415
Loss before income taxes	(4,166,437)	(4,678,390)
Income taxes - current	3,220	4,840
Total income taxes	3,220	4,840
Loss	(4,169,657)	(4,683,230)

AnGes MG, Inc
Nonconsolidated Statements of Changes in Net Assets
(In thousands of yen)
(Unaudited)

Year ended Dec.31, 2015 (From Jan.1 to Dec.31, 2015)

	Shareholders' equity				
	Capital stock	Capital surplus	Retained earnings	Treasury shares	Total shareholders' equity
		Legal capital surplus	Other retained earnings Retained earnings brought forward		
Balance at the beginning of the period	14,847,066	13,157,806	(20,574,854)	(11)	7,430,006
Changes of items during the period					
Issuance of new shares	367,875	367,875			735,750
Net loss			(4,169,657)		(4,169,657)
Purchase of treasury shares				-	-
Net changes of items other than shareholders' equity					-
Total changes of items during the period	367,875	367,875	(4,169,657)	-	(3,433,907)
Balance at the end of current period	15,214,941	13,525,681	(24,744,512)	(11)	3,996,098

	Valuation and translation adjustments	Subscription rights to shares	Total net assets
	Valuation difference on available-for-sale securities		
Balance at the beginning of the period	17,005	109,165	7,556,177
Changes of items during the period			
Issuance of new shares			735,750
Net loss			(4,169,657)
Purchase of treasury shares			-
Net changes of items other than shareholders' equity	(46,948)	(57,725)	(104,673)
Total changes of items during the period	(46,948)	(57,725)	(3,538,581)
Balance at the end of current period	(29,942)	51,439	4,017,595

Year ended Dec.31, 2016 (From Jan.1 to Dec.31, 2016)

	Shareholders' equity				
	Capital stock	Capital surplus	Retained earnings	Treasury shares	Total shareholders' equity
		Legal capital surplus	Other retained earnings Retained earnings brought forward		
Balance at the beginning of the period	15,214,941	13,525,681	(24,744,512)	(11)	3,996,098
Changes of items during the period					
Issuance of new shares	2,436,249	2,436,249			4,872,498
Net loss			(4,683,230)		(4,683,230)
Purchase of treasury shares				(11)	(11)
Net changes of items other than shareholders' equity					-
Total changes of items during the period	2,436,249	2,436,249	(4,683,230)	(11)	189,256
Balance at the end of current period	17,651,190	15,961,930	(29,427,742)	(23)	4,185,354

	Valuation and translation adjustments	Subscription rights to shares	Total net assets
	Valuation difference on available-for-sale securities		
Balance at the beginning of the period	(29,942)	51,439	4,017,595
Changes of items during the period			
Issuance of new shares			4,872,498
Net loss			(4,683,230)
Purchase of treasury shares			(11)
Net changes of items other than shareholders' equity	(386,837)	(42,117)	(428,954)
Total changes of items during the period	(386,837)	(42,117)	(239,698)
Balance at the end of current period	(416,779)	9,322	3,777,897

Projects --- Current pipeline status

<Self-developed products>

Segment	Project	Target indications	Region	Development stage	Alliance partners
Medicine	HGF Plasmid	Peripheral Arterial Disease (PAD)	Japan	Completed Phase III, additional study ongoing (physician-led study)*	Mitsubishi Tanabe Pharma Corporation (JP) <i>Marketing Rights</i>
			US	Planning for Phase III	Mitsubishi Tanabe Pharma Corporation (JP) <i>Marketing Rights</i>
		Japan	Phase I / II	Available	
	Hypertension DNA Therapeutic Vaccine	Hypertension		Preclinical Preparing for Phase I (Australia)	Available
	NF-κB Decoy Oligo DNA	Atopic Dermatitis	Japan	(Ointment drug) Completed Phase III**	Shionogi & Co., LTD. (JP) <i>Marketing Rights < World ></i>
Disc Degeneration			Preclinical Preparing for Phase I / II	Available	

* Drug application under conditional approval system is planned for HGF Plasmid in Japan.

** The study did not show statistically significant difference between the NF-κB Decoy Oligonucleotide treated group and the placebo group in the primary endpoint.

<In-licenced program>

Segment	Project/ Product name	Target indications	Rights of AnGes	Development stage	Alliance partners
Medicine	CIN Therapeutic Vaccine	Cervical Precancerous Lesion	Development & Marketing rights for Japan, US, UK & China*	Investigator-initiated study <Japan>	Bio Leaders Corporation (South Korea) Licensing-out to Morishita Jintan Co., Ltd
	Allovectin®	Cancer	Development & marketing rights for Asia	Under review	Vical, Inc. (US)